Search trials – HealthDB

Активни:

Намерени 3,079 изпитвания Стр. 154 от 154

Active (not recruiting) Phase 2/3

Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

Gastric Cancer

Gastric cancer remains a significant global public health problem. Although in developed countries its incidence has dramatically decreased, on a worldwide scale it is still a leading cause of cancer-related deaths. Surgery is the only potentially curative treatment for gastric cancer. Although the survival rates for patients with early stage disease (stage 1A and 1B) are good, this subgroup of patients constitutes only 20% of those undergoing resection. The majority of patients will have locally advanced or metastatic disease at presentation, which has an extremely poor prognosis. The current five-year survival rate for gastric cancer in Western countries is approximately 20-30%, a figure that has improved little over the past 30 years. The intervention arm in TOPGEAR consists of pre-operative chemotherapy, pre-operative chemoradiotherapy, surgery and post-operative chemotherapy. The control arm consists of pre-operative chemotherapy, surgery and post-operative chemotherapy. The primary objective of TOPGEAR is to investigate whether the addition of chemoradiotherapy to chemotherapy is superior to chemotherapy alone in the neoadjuvant setting by improving pathological complete response rates in the first instance, and subsequently overall survival, in patients undergoing adequate surgery (D1+ dissection) for resectable gastric cancer.

Начало: 01.09.2009 Край: 31.12.2026 Възраст: от 18 г. Treatment

Australia, Belgium, Canada +7 Australasian Gastro-Intestinal Trials Group NCT01924819

Active (not recruiting) Phase 3

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Adult Kidney Wilms Tumor Beckwith-Wiedemann Syndrome Childhood Kidney Wilms Tumor Diffuse Hyperplastic Perilobar Nephroblastomatosis +6

This phase III trial studies how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.

Начало: 13.07.2009 Възраст: до 29 г. Treatment

Australia, Canada, Israel +3 Children's Oncology Group NCT00945009

Active (not recruiting)

Radiotherapy - Adjuvant Versus Early Salvage

Prostate Cancer

Radical prostatectomy (RP) is the most common curative approach offered to men with newly diagnosed prostate cancer. Unfortunately, up to half of these patients will have factors placing them at high risk of their cancer recurring. Having radiotherapy after RP is known to improve cure rates, but what is not known is whether it should be given straight after the operation or only when there is a rising PSA after surgery indicating active cancer. Immediate RT may not benefit all men, and can cause serious side effects such as bladder and bowel problems and impotence. International lack of consensus on the optimal timing of RT has resulted in varied clinical practice. This phase 3 trial will compare the two approaches.

Начало: 03.03.2009 Край: 01.12.2026 Възраст: от 18 г. Treatment

Australia, New Zealand Trans Tasman Radiation Oncology Group NCT00860652

Active (not recruiting)

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Childhood Malignant Neoplasm

This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.

Начало: 27.02.2009 Възраст: от 1 г.

Australia, Canada, New Zealand +2 Children's Oncology Group NCT00772200

Active (not recruiting) Phase 1

Phase I Comparative Bioavailability Study

Solid Tumors

The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients

Начало: 27.10.2008 Край: 31.03.2026 Възраст: 18–130 г. Basic science

Australia, Belgium, Switzerland +1 AstraZeneca NCT00777582

Active (not recruiting) Phase 2

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Neoplasm Metastasis

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.

Начало: 16.10.2008 Край: 30.04.2030 Възраст: от 18 г. Treatment

Australia, Belgium, Brazil +29 Genentech, Inc. NCT00781612

Active (not recruiting)

Australian Multicentre Colonic Endoscopic Mucosal Resection Study

Colonic Polyps

A prospective, multicentre, observational study of all patients referred for endoscopic resection of sessile colorectal polyps sized ≥20 mm conducted with intention to treat analysis.

Начало: 01.09.2008 Край: 01.09.2026 Възраст: от 18 г.

Australia Professor Michael Bourke NCT01368289

Active (not recruiting) Phase 2

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Brain and Central Nervous System Tumors

RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important part of the two clinical trials which resulted in the best survival results for children less than 3 years of age with medulloblastoma. Most patients treated on this trial will also receive radiation which is carefully targeted to the area of the tumor. This type of radiation (focal conformal or proton beam radiotherapy) may result in fewer problems with thinking and learning than radiation to the whole brain and spinal cord. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system tumors.

Начало: 17.12.2007 Край: 01.04.2026 Възраст: до 5 г. Treatment

Australia, United States St. Jude Children's Research Hospital NCT00602667

Active (not recruiting) Phase 3

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

Brain and Central Nervous System Tumors

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma. PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.

Начало: 01.12.2007 Край: 01.12.2029 Възраст: 18–120 г. Treatment

Australia, Belgium, Canada +9 European Organisation for Research and Treatment of Can NCT00626990

Active (not recruiting)

Psoriasis Longitudinal Assessment and Registry

Psoriasis

The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (PsA); and clinical and quality of life outcomes.

Начало: 21.06.2007 Край: 31.12.2030 Възраст: 18–99 г.

Argentina, Australia, Belgium +17 Janssen Scientific Affairs, LLC NCT00508547

Active (not recruiting) Phase 3

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Anaplastic Medulloblastoma Medulloblastoma

This phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Chemotherapy drugs, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Carboplatin may make tumor cells more sensitive to radiation therapy. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating brain tumors.

Начало: 23.05.2007 Край: 30.06.2028 Възраст: 3–22 г. Treatment

Australia, Canada, Netherlands +2 Children's Oncology Group NCT00392327

Active (not recruiting) Phase 3

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor

This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more tumor cells.

Начало: 30.04.2007 Край: 18.11.2026 Възраст: до 29 г. Treatment

Australia, Canada, Israel +4 Children's Oncology Group NCT00379340

Active (not recruiting) Phase 3

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Stage I Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor

This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors.Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.

Начало: 06.11.2006 Край: 31.03.2026 Възраст: до 29 г. Treatment

Australia, Canada, Israel +4 Children's Oncology Group NCT00352534

Active (not recruiting)

Study of Kidney Tumors in Younger Patients

Adult Cystic Nephroma Anaplastic Kidney Wilms Tumor Angiolipoma Cellular Congenital Mesoblastic Nephroma +21

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Начало: 27.02.2006 Възраст: до 29 г.

Australia, Canada, Israel +4 Children's Oncology Group NCT00898365

Active (not recruiting) Phase 2

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Ann Arbor Stage I Childhood Hodgkin Lymphoma Ann Arbor Stage II Childhood Hodgkin Lymphoma Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma

This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). Surgery may be an effective treatment for LPHD. Drugs used in chemotherapy, such as doxorubicin, vincristine, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more cancer cells.

Начало: 02.01.2006 Край: 31.12.2030 Възраст: 1–21 г. Treatment

Australia, Canada, Israel +3 Children's Oncology Group NCT00107198

Active (not recruiting)

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

Childhood Malignant Neoplasm

This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.

Начало: 25.03.2004 Край: 31.03.2026 Възраст: до 99 г.

Australia, Canada, Puerto Rico +2 Children's Oncology Group NCT00082745

Active (not recruiting)

FA Clinical Outcome Measures

Friedreich Ataxia Neuro-Degenerative Disease

This multicenter natural history study aims to expand the network of clinical research centers in FA, and to provide a framework for facilitating therapeutic interventions. In addition, this study will lead to the development of valid yet sensitive clinical measures crucial to outcome assessment of patients with Friedreich's Ataxia. This study will support genetic modifier studies, biomarker studies, and frataxin protein level assessments by building a sample repository. This natural history study is no longer recruiting under this protocol NCT03090789 but remains actively recruiting under the harmonized study (UNIFAI) NCT06016946.

Начало: 01.01.2001 Край: 01.01.2030 Възраст: 4–80 г.

Australia, Canada, India +2 Friedreich's Ataxia Research Alliance NCT03090789

Active (not recruiting)

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Ganglioneuroblastoma Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Regional Neuroblastoma +2

This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

Начало: 06.11.2000 Възраст: до 30 г.

Australia, Canada, Netherlands +5 Children's Oncology Group NCT00904241

Active (not recruiting) Phase 3

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Melanoma (Skin)

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.

Начало: 25.03.1999 Край: 01.12.2026 Възраст: от 18 г. Treatment

Australia, Canada, South Africa +1 ECOG-ACRIN Cancer Research Group NCT00003641

1 … 152 153 154